Jul. 17 at 12:40 PM
$IMMX
Thanks for the link @Splat00n
NEXICART-3 just showed up on CT DB posted 7/16.
This is the randomized Phase 3 confirmatory trial, NXC-201 vs Dara-CyBorD, 260 patients, open label.
Study start estimated Jan 2027, in line with prior guidance.
Classic confirmatory design with CHR rate at 24 months and MOD-PFS at 60 months as primaries.
What this tells you is management is lining up post-marketing commitments while the pivotal readout is still pending. Execution looks clean heading into September.
A sign the regulatory runway for last-line AL amyloidosis is being built with discipline.
